The global orexin receptor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Orexins are also known as hypocretins. They are two neuropeptides secreted from orexin-containing neurons, mainly in the lateral hypothalamus (LH). They play a vital regulatory role in many physiological processes such as feeding behavior, sleep–wake rhythm, reward and addiction and energy balance. The major factor driving the growth of the market is the rising prevalence of depressive disorder across the globe. 

According to the National Institute of Mental Health (NHIM), in 2019, an estimated 19.4 million adults in the US had at least one major depressive episode which represented 7.8% of adults. Furthermore, according to World Health Organization (WHO), depression is a leading cause of disability globally with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years in 2021. Hence, the increasing prevalence of the depressive disorder is driving the demand for orexin receptors owing to their application as an anti-depressant which in turn is driving the growth of the market.

Some major players in the market include Merck & Co. Inc., GlaxoSmithKline plc, and Eisai Co., Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2020, Eisai Co., Ltd. announced the launch of its in-house-discovered and developed orexin receptor antagonist DAYVIGO 2.5 mg, 5 mg, 10 mg tablets (lemborexant) in Japan. It is used for the treatment of insomnia. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Merck & Co. Inc., GlaxoSmithKline plc, and Eisai Co., Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Orexin Receptor Market Report by Segment

By Type

• Orexin 1 Receptor

• Orexin 2 Receptor

By Application

• Insomnia

• Sleep Disorders

• Major Depressive Disorder

• Other

Global Orexin Receptor Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa